Prior studies have noted that the methylation of epoxide hydrolase 3 (EPHX3) is significantly associated with the prognosis of prostate cancer and its inclusion into clinical practice has been suggested as a tool to a more accurate prediction of which patients may experience prostate cancer recurrence. Here, EPHX3 is linked to prostate carcinoma.